Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma. The assay is now ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s PD-L1 IHC 22C3 pharmDx assay for ...
Correlation of β-catenin expression in non-small cell lung cancer to prognosis and CD8 positive cells infiltration. This is an ASCO Meeting Abstract from the 2018 ASCO-SITC Clinical Immuno-Oncology ...
Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx™ ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Third paragraph of release should read: The expanded approvals for PD-L1 IHC 22C3 pharmDx and KEYTRUDA means that these patients now have the possibility of ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx assay is now labelled for use in TNBC in the European Union. PD-L1 expression ...
Agilent Technologies A is leaving no stone unturned to bolster diagnostic tool offerings in a bid to strengthen its Diagnostics and Genomics Group (DGG) segment. Notably, Agilent received FDA approval ...
Announcement marks the seventh cancer type for which PD-L1 IHC 22C3 pharmDx has gained approval in the US SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced it ...
Agilent Technologies A has bolstered presence in the clinical and diagnostic testing market of Europe by expanding the use of PD-L1 IHC 22C3 pharmDx assay in patients suffering from esophageal cancer ...
Dako has announced the CE Mark certification for use of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer (NSCLC) is likely to respond to ...
Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer A total of 871 patient samples were retrospectively tested using the VENTANA PD-L1 (SP263) assay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback